University of Pennslyvania Health Systems
Office of Public Affairs
399 South 34th Street, Suite 2002, Penn Tower, Philadelphia, PA 19104-5653

Contact:
Holly Auer

215-349-5659

Holly.auer@uphs.upenn.edu


Penn Researchers Find Monkeys Able to Fend Off AIDS-like Symptoms with Enhanced HIV Vaccine

Findings Could Point to Novel Ways to Boost Immune Response in Humans

 

(PHILADELPHIA) – Researchers at the University of Pennsylvania School of Medicine have discovered that using an immune system gene to enhance a vaccine used to study HIV in macaque monkeys provides the animals with greater protection against simian HIV (SHIV) than an unmodified vaccine. This multi-year study found that the addition of a molecule called Interleukin-15 effectively boosts the effects of a vaccine derived from the DNA of simian HIV. The study illustrates that DNA vaccine effectiveness can be improved by the inclusion of specific immune adjuvants, or helpers.

 

The findings are published in last week’s online edition of the Proceedings of the National Academy of Sciences.

 

“DNA vaccine technology has great promise for the development of vaccines and immune therapeutics for a variety of infectious diseases and cancers,” says senior author David B. Weiner, PhD, Professor of Pathology and Laboratory Medicine at Penn. While previous studies have established that the technology can induce immune responses safely, “improving the immune potency of this platform is critical for further development in humans.”

 

The research builds on previous work aimed at engineering a more potent immune response to SHIV DNA vaccine technology. Mouse model studies previously showed that the cytokine IL-15 -- a substance that can improve the body's natural response to infection and disease -- helps better immune responses and protection, while this study mirrors those findings in a larger, non-human primate species.

 

In this study, the group of macaques that was injected with the vaccine containing a loop of DNA enabling them to make IL-15 developed no signs of AIDS-like symptoms when exposed to live SHIV, compared to four animals in the control group that received only the DNA vaccine. The modified vaccine appeared to help suppress viral replication among the IL-15 group.

 

Next, Weiner’s team will study the protected macaques to determine the actual mechanism of their protection, and seek out any pockets of the virus that may be hiding in specific immune compartments. The approach will also be tested for safety and immunogenicity in humans through the HIV Vaccine Trials Network.

 

The lead author of the study is Dr. Jean Boyer, of the University of Pennsylvania.  Co-authors include researchers from the National Cancer Institute, the Southern Research Institute in Frederick, MD, the National Institute of Allergy and Infectious Diseases in Bethesda, MD, Genomix (San Diego, CA) and Wyeth (Pearl River, N.Y.). The research was supported by the National Institutes of Health and the Intramural Research Program of the NIH.

###

 

PENN Medicine is a $3.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is currently ranked #3 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals — its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s “Honor Roll” hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center — a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.


Release available online at http://www.uphs.upenn.edu/news/News_Releases/nov07/HIV-vaccine.html